NASDAQ:SIBN - SI-Bone Stock Price, News, & Analysis

$18.00
+0.02 (+0.11 %)
(As of 06/27/2019 04:16 AM ET)
Today's Range
$17.8050
Now: $18.00
$18.1850
50-Day Range
$15.73
MA: $16.88
$18.13
52-Week Range
$14.08
Now: $18.00
$23.03
Volume173,112 shs
Average Volume102,561 shs
Market Capitalization$442.15 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
SI-BONE, Inc., a medical device company, develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. It offers iFuse, an implant system to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. The company was founded in 2008 and is headquartered in Santa Clara, California.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SIBN
CUSIPN/A
CIKN/A
Phone408-207-0700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$55.38 million
Book Value$3.71 per share

Profitability

Miscellaneous

Employees183
Market Cap$442.15 million
Next Earnings Date8/14/2019 (Estimated)
OptionableNot Optionable

Receive SIBN News and Ratings via Email

Sign-up to receive the latest news and ratings for SIBN and its competitors with MarketBeat's FREE daily newsletter.

SI-Bone (NASDAQ:SIBN) Frequently Asked Questions

What is SI-Bone's stock symbol?

SI-Bone trades on the NASDAQ under the ticker symbol "SIBN."

How were SI-Bone's earnings last quarter?

SI-Bone Inc (NASDAQ:SIBN) released its quarterly earnings results on Wednesday, May, 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.25) by $0.13. The company earned $14.99 million during the quarter. View SI-Bone's Earnings History.

When is SI-Bone's next earnings date?

SI-Bone is scheduled to release their next quarterly earnings announcement on Wednesday, August 14th 2019. View Earnings Estimates for SI-Bone.

What price target have analysts set for SIBN?

4 equities research analysts have issued 1 year target prices for SI-Bone's shares. Their predictions range from $23.00 to $27.00. On average, they anticipate SI-Bone's stock price to reach $24.75 in the next twelve months. This suggests a possible upside of 37.5% from the stock's current price. View Analyst Price Targets for SI-Bone.

What is the consensus analysts' recommendation for SI-Bone?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SI-Bone in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for SI-Bone.

Has SI-Bone been receiving favorable news coverage?

Media headlines about SIBN stock have trended neutral recently, according to InfoTrie Sentiment. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. SI-Bone earned a media sentiment score of 0.5 on InfoTrie's scale. They also gave news stories about the company a news buzz of 9.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for SI-Bone.

Are investors shorting SI-Bone?

SI-Bone saw a decrease in short interest during the month of June. As of June 15th, there was short interest totalling 275,400 shares, a decrease of 13.1% from the May 15th total of 316,800 shares. Based on an average daily trading volume, of 118,600 shares, the short-interest ratio is presently 2.3 days. Approximately 1.9% of the company's shares are sold short. View SI-Bone's Current Options Chain.

Who are some of SI-Bone's key competitors?

What other stocks do shareholders of SI-Bone own?

Based on aggregate information from My MarketBeat watchlists, some companies that other SI-Bone investors own include Mitchells & Butlers (MAB), ADMA Biologics (ADMA), Aeglea Bio Therapeutics (AGLE), Aqua Metals (AQMS), Ascendis Pharma A/S (ASND), eHealth (EHTH), Evolus (EOLS), Iovance Biotherapeutics (IOVA), MarketAxess (MKTX) and Opko Health (OPK).

Who are SI-Bone's key executives?

SI-Bone's management team includes the folowing people:
  • Mr. Jeffrey W. Dunn, CEO, Pres & Chairman (Age 63)
  • Dr. Mark A. Reiley M.D., Founder & Director (Age 68)
  • Ms. Laura A. Francis, Chief Financial Officer (Age 52)
  • Mr. Anthony J. Recupero, Chief Commercial Officer (Age 61)
  • Dr. Scott A. Yerby, Chief Technology Officer (Age 51)

When did SI-Bone IPO?

(SIBN) raised $84 million in an IPO on Wednesday, October 17th 2018. The company issued 6,000,000 shares at $13.00-$15.00 per share. Morgan Stanley and BofA Merrill Lynch acted as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.

Who are SI-Bone's major shareholders?

SI-Bone's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Redmile Group LLC (2.19%), Federated Investors Inc. PA (1.51%), Gilder Gagnon Howe & Co. LLC (1.44%), Spark Investment Management LLC (0.19%), Granite Investment Partners LLC (0.18%) and Victory Capital Management Inc. (0.04%). Company insiders that own SI-Bone stock include Anthony J Recupero, David P Bonita, Laura Francis, Mark A Reiley, Michael A Pisetsky, Scott A Yerby, Skyline Venture Partners V Lp and W Carlton Reckling. View Institutional Ownership Trends for SI-Bone.

Which institutional investors are selling SI-Bone stock?

SIBN stock was sold by a variety of institutional investors in the last quarter, including Redmile Group LLC, Victory Capital Management Inc. and Gilder Gagnon Howe & Co. LLC. Company insiders that have sold SI-Bone company stock in the last year include Anthony J Recupero, Laura Francis, Mark A Reiley, Michael A Pisetsky, Scott A Yerby and W Carlton Reckling. View Insider Buying and Selling for SI-Bone.

Which institutional investors are buying SI-Bone stock?

SIBN stock was bought by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, Spark Investment Management LLC, Granite Investment Partners LLC and Valeo Financial Advisors LLC. Company insiders that have bought SI-Bone stock in the last two years include David P Bonita and Skyline Venture Partners V Lp. View Insider Buying and Selling for SI-Bone.

How do I buy shares of SI-Bone?

Shares of SIBN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is SI-Bone's stock price today?

One share of SIBN stock can currently be purchased for approximately $18.00.

How big of a company is SI-Bone?

SI-Bone has a market capitalization of $442.15 million and generates $55.38 million in revenue each year. The company earns $-17,450,000.00 in net income (profit) each year or ($0.71) on an earnings per share basis. SI-Bone employs 183 workers across the globe.View Additional Information About SI-Bone.

What is SI-Bone's official website?

The official website for SI-Bone is http://si-bone.com/.

How can I contact SI-Bone?

SI-Bone's mailing address is 471 EL CAMINO REAL SUITE 101, SANTA CLARA CA, 95050. The company can be reached via phone at 408-207-0700 or via email at [email protected]


MarketBeat Community Rating for SI-Bone (NASDAQ SIBN)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  26 (Vote Outperform)
Underperform Votes:  37 (Vote Underperform)
Total Votes:  63
MarketBeat's community ratings are surveys of what our community members think about SI-Bone and other stocks. Vote "Outperform" if you believe SIBN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SIBN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/27/2019 by MarketBeat.com Staff

Featured Article: What is the Coverage Ratio?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel